IL286839B - Propyne-indole compounds - Google Patents

Propyne-indole compounds

Info

Publication number
IL286839B
IL286839B IL286839A IL28683921A IL286839B IL 286839 B IL286839 B IL 286839B IL 286839 A IL286839 A IL 286839A IL 28683921 A IL28683921 A IL 28683921A IL 286839 B IL286839 B IL 286839B
Authority
IL
Israel
Prior art keywords
group
compound
alkyl
halo
alkenyl
Prior art date
Application number
IL286839A
Other languages
English (en)
Hebrew (he)
Other versions
IL286839A (en
Original Assignee
Pmv Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pmv Pharmaceuticals Inc filed Critical Pmv Pharmaceuticals Inc
Publication of IL286839A publication Critical patent/IL286839A/en
Publication of IL286839B publication Critical patent/IL286839B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL286839A 2016-02-19 2017-02-17 Propyne-indole compounds IL286839B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662297450P 2016-02-19 2016-02-19
PCT/US2017/018511 WO2017143291A1 (en) 2016-02-19 2017-02-17 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Publications (2)

Publication Number Publication Date
IL286839A IL286839A (en) 2021-10-31
IL286839B true IL286839B (en) 2022-08-01

Family

ID=59625486

Family Applications (2)

Application Number Title Priority Date Filing Date
IL286839A IL286839B (en) 2016-02-19 2017-02-17 Propyne-indole compounds
IL261175A IL261175B (en) 2016-02-19 2018-08-15 Propyne-indole compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL261175A IL261175B (en) 2016-02-19 2018-08-15 Propyne-indole compounds

Country Status (10)

Country Link
US (4) US10138219B2 (enExample)
EP (1) EP3416638A4 (enExample)
JP (1) JP6956098B2 (enExample)
KR (1) KR102868217B1 (enExample)
CN (2) CN119161324B (enExample)
AU (1) AU2017221472B2 (enExample)
CA (2) CA3215564C (enExample)
IL (2) IL286839B (enExample)
MX (1) MX383904B (enExample)
WO (1) WO2017143291A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383904B (es) 2016-02-19 2025-03-14 Pmv Pharmaceuticals Inc Métodos y composiciones para restablecer la función de p53 mutante.
US11814373B2 (en) * 2019-09-23 2023-11-14 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
EP4149459A4 (en) * 2020-05-12 2024-05-22 PMV Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION
CN111686127B (zh) * 2020-06-04 2022-02-15 华南理工大学 锌铁纳米材料在降解突变p53蛋白中的应用
CN113750246B (zh) * 2020-06-04 2023-12-05 华南理工大学 ZIF-8纳米材料在降解广谱突变p53蛋白中的应用
US12570645B2 (en) 2020-06-22 2026-03-10 Pmv Pharmaceuticals, Inc. Uses of p53 x-ray co-crystal structures
WO2021262596A1 (en) * 2020-06-22 2021-12-30 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
EP4168411A4 (en) * 2020-06-22 2024-07-24 PMV Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING FUNCTION IN P53 MUTANTS
CN116249689A (zh) * 2020-06-24 2023-06-09 皮姆维制药公司 用于再激活突变p53的化合物的伴随诊断工具
WO2021262483A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
CA3183081A1 (en) * 2020-06-24 2021-12-30 Arnold Levine Combination therapy for treatment of cancer
US11667636B2 (en) 2020-12-24 2023-06-06 Escient Pharmaceuticals, Inc. Modulators of Mas-related G-protein receptor X2 and related products and methods
WO2022213975A1 (en) * 2021-04-08 2022-10-13 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53
UY39890A (es) * 2021-08-10 2023-03-31 Jacobio Pharmaceuticals Co Ltd Compuestos con diana en mutante de p53
CN117916230A (zh) * 2021-08-27 2024-04-19 杭州紫晶医药科技有限公司 作为p53调节剂的化合物
WO2023147419A2 (en) 2022-01-27 2023-08-03 Pmv Pharmaceuticals, Inc. Deuterated compounds for restoring mutant p53 function
WO2024017384A1 (zh) * 2022-07-22 2024-01-25 深圳众格生物科技有限公司 恢复p53突变功能的化合物及其应用
WO2024041503A1 (en) * 2022-08-22 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53
WO2024083223A1 (zh) * 2022-10-21 2024-04-25 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
CN120265637A (zh) * 2022-12-08 2025-07-04 北京加科思新药研发有限公司 靶向p53突变体的化合物
WO2025031471A1 (zh) * 2023-08-09 2025-02-13 德睿智药(苏州)新药研发有限公司 用于调节p53功能的新型杂环类化合物
AU2024295989B2 (en) 2023-10-20 2026-08-13 Nutshell Therapeutics (Shanghai) Co., Ltd. N-sulfonamide nitrogen-containing fused heterocyclic compound, and application thereof
WO2025242903A1 (en) * 2024-05-24 2025-11-27 Onco3R Therapeutics Bv Compounds and pharmaceutical compositions thereof for the treatment of proliferative diseases
WO2026025042A1 (en) 2024-07-26 2026-01-29 Dana-Farber Cancer Institute, Inc. P53 targeting compounds and uses thereof
WO2026067649A1 (zh) * 2024-09-27 2026-04-02 奇树医药公司 恢复p53突变功能的化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032175A2 (en) * 1998-12-02 2000-06-08 Pfizer Products Inc. METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
EP1689710A1 (en) * 2003-11-25 2006-08-16 Novo Nordisk A/S Indole derivatives for use as chemical uncoupler
US7601714B2 (en) 2004-07-08 2009-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
EP2268658B1 (en) 2008-03-13 2015-12-09 Universita'Degli Studi di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
RS54165B1 (sr) * 2008-04-16 2015-12-31 Karo Bio Ab Novi ligandi za estrogenski receptor
GB0808282D0 (en) * 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
HUE027755T2 (en) * 2009-03-27 2016-11-28 Merck Sharp & Dohme Inhibitors of hepatitis C virus replication
DE102010049877A1 (de) 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
RU2598842C2 (ru) 2011-01-20 2016-09-27 Мерк Шарп Энд Домэ Корп. Антагонисты рецептора минералокортикоидов
GB201110390D0 (en) 2011-06-20 2011-08-03 Medical Res Council Compounds for use in stabilising p53 mutants
SG10201601840RA (en) * 2011-09-09 2016-04-28 Agency Science Tech & Res P53 activating peptides
WO2013101911A2 (en) 2011-12-28 2013-07-04 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
US8822689B2 (en) 2012-09-19 2014-09-02 Merial Limited Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
EP3145512B1 (en) * 2014-05-19 2019-07-17 Jiangsu Hengrui Medicine Co., Ltd. Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
CN104672241B (zh) * 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
MX383904B (es) 2016-02-19 2025-03-14 Pmv Pharmaceuticals Inc Métodos y composiciones para restablecer la función de p53 mutante.

Also Published As

Publication number Publication date
US20170240525A1 (en) 2017-08-24
MX2018009947A (es) 2019-01-21
MX383904B (es) 2025-03-14
CA3010847C (en) 2025-09-23
CA3215564C (en) 2026-04-28
CN119161324A (zh) 2024-12-20
EP3416638A4 (en) 2019-07-17
CA3010847A1 (en) 2017-08-24
CN109069481A (zh) 2018-12-21
JP2019512465A (ja) 2019-05-16
BR112018016890A2 (pt) 2019-02-12
US20190119249A1 (en) 2019-04-25
KR20180138200A (ko) 2018-12-28
AU2017221472A1 (en) 2018-07-26
KR102868217B1 (ko) 2025-10-14
IL261175A (en) 2018-10-31
CA3215564A1 (en) 2017-08-24
US20210002252A1 (en) 2021-01-07
AU2017221472B2 (en) 2023-01-05
US20220213062A1 (en) 2022-07-07
WO2017143291A1 (en) 2017-08-24
IL261175B (en) 2021-10-31
JP6956098B2 (ja) 2021-10-27
US10138219B2 (en) 2018-11-27
CN119161324B (zh) 2025-10-17
IL286839A (en) 2021-10-31
US10640485B2 (en) 2020-05-05
EP3416638A1 (en) 2018-12-26
US11339141B2 (en) 2022-05-24

Similar Documents

Publication Publication Date Title
JP7555938B2 (ja) アンドロゲン受容体を標的とするユビキチン化のための二官能性化合物および方法
KR100387359B1 (ko) 항-염증성,비알러지성및항-혈전성을가지는니트로화합물들과그들의조성물들
DK2303021T3 (en) RELATIONSHIPS FOR TREATING CANCER
EA200600527A1 (ru) Активирующее ppar соединение и содержащая его фармацевтическая композиция
CA2881057A1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
RU2008134534A (ru) 3,5-ди(арилили гетероарил)изоксазолы и 1,2,4-оксадиазолы в качестве агонистов рецентора s1p1, иммунодепрессантных и противовоспалительных агентов
RU2007125726A (ru) Новое производное антраниловой кислоты или его соль
AR061663A1 (es) Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados.
RU2013147629A (ru) Соединения для лечения метаболического синдрома
CA2895606A1 (fr) Saturated nitrogen and n-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria
JP2019524781A (ja) Ｔｌｒ２二量体化調節剤としての脂質置換アミノ１，２−ジオール化合物および脂質置換アミノ１，３−ジオール化合物
ATE482933T1 (de) Sulfopyrrolderivate
WO2017219083A1 (en) Activators of hiv latency
ES2719115T3 (es) Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck
WO2007147770A3 (en) Substituted phenyl methanone derivatives
CA2936707A1 (en) Diaminoguanidine derivatives and application thereof in preparation of animal growth promoters used in feed
AU2013366494B2 (en) Spiroisoxazoline compounds having an activity potentiating the activity of an antibiotic
JP7815213B2 (ja) ベンジルアミン誘導体、その調製方法およびその用途
EP3180307B1 (en) Process for the synthesis of dapsone and its intermediates
EP2716639A1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
EA201000832A1 (ru) Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции
KR20220110235A (ko) PDIA4 저해제 및 β-세포 발병을 저해하고 당뇨병을 치료하기 위한 이의 용도
Sharada et al. Synthesis, molecular docking and biological activity of 4-aminoantipyrine dithiocarbamate derivatives
Aljamali et al. Synthesis, characterization and study of chromatography behavior of novel (azo–anil)-heterocyclic compounds
WO2022256609A1 (en) Modulators of integrated stress response pathway